|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
gptkb:Mavenclad
gptkb:Allergan
|
|
gptkbp:awards
|
gptkb:Diversity_Inc_Top_50_Companies_for_Diversity
Best Places to Work
Fortune 500 Company
Human Rights Campaign Corporate Equality Index
Top Employer in Europe
|
|
gptkbp:ceo
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:clinical_trial
|
multiple ongoing trials
|
|
gptkbp:employees
|
approximately 50,000
|
|
gptkbp:focus_area
|
oncology
neuroscience
immunology
virology
women's health
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:headquarters
|
gptkb:North_Chicago,_Illinois,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abb Vie Ltd.
|
|
gptkbp:market_cap
|
approximately $200 billion (2022)
|
|
gptkbp:notable_products
|
gptkb:Humira
gptkb:Venclexta
gptkb:Rinvoq
gptkb:Skyrizi
gptkb:Imbruvica
|
|
gptkbp:parent_company
|
gptkb:Abbott_Laboratories
|
|
gptkbp:partnership
|
gptkb:Duke_University
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Chicago
|
|
gptkbp:research_and_development
|
$6 billion (2022)
|
|
gptkbp:revenue
|
approximately $56 billion (2022)
|
|
gptkbp:subsidiary
|
gptkb:Abb_Vie_Inc.
gptkb:Abb_Vie_Biotherapeutics
gptkb:Abb_Vie_Deutschland_Gmb_H
Abb Vie Ltd. (UK)
Abb Vie Srl
|
|
gptkbp:sustainability_initiatives
|
gptkb:healthcare_organization
gptkb:sports_team
gptkb:Community_Center
Environmental Sustainability Program
Patient Access Program
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie_S.r.l.
|
|
gptkbp:bfsLayer
|
4
|